Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

Anavex Life Sciences Corp.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

ADAS-COG13 DIFFERENCE 12.78 (P < 0.0001) WITH ORAL BLARCAMESINE TREATMENT COMPARED TO ADNI CONTROL GROUP AT WEEK 144

ANAVEX LIFE SCIENCES ANNOUNCES CONTINUED LONG-TERM BENEFIT FROM ORAL BLARCAMESINE COMPARED TO DECLINE OBSERVED IN THE ALZHEIMER'S DISEASE NEUROIMAGING INITIATIVE (ADNI) CONTROL GROUP

PRESENTATION TITLE: ADVANCING ALZHEIMER'S DISEASE CARE: CONVENIENCE FOR BOTH PATIENTS AND FAMILIES WITH ORAL BLARCAMESINE PRESENTATION TITLE: ADVANCING ALZHEIMER'S DISEASE CARE: CONVENIENCE FOR BOTH PATIENTS AND FAMILIES WITH ORAL BLARCAMESINE

ANAVEX LIFE SCIENCES ANNOUNCES PRESENTATION AT THE 35TH ALZHEIMER EUROPE CONFERENCE CONNECTING SCIENCE AND COMMUNITIES: THE FUTURE OF DEMENTIA CARE'

ANAVEX3-71-002 TRIAL ACHIEVED ITS PRIMARY ENDPOINT DEMONSTRATING SAFETY AND TOLERABILITY IN BOTH MALE AND FEMALE ADULTS

ANAVEX LIFE SCIENCES ANNOUNCES SUCCESSFUL DEVELOPMENT OF ONCE-DAILY ORAL TABLET FORMULATION FOR THE ANAVEX3-71 PROGRAM

ANAVEX3-71-SZ-001 ACHIEVED ITS PRIMARY ENDPOINT DEMONSTRATING SAFETY AND TOLERABILITY IN ADULTS WITH SCHIZOPHRENIA ENCOURAGING TRENDS OBSERVED IN BIOMARKERS SUPPORT CONTINUED DEVELOPMENT NEW YORK, OCT. 02, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. ("ANAVEX" OR THE "COMPANY") (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING DIFFERENTIATED THERAPEUTICS FOR THE TREATMENT OF NEURODEGENERATIVE, NEURODEVELOPMENTAL, AND NEUROPSYCHIATRIC DISORDERS, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM ITS PLACEBO-CONTROLLED PHASE 2 CLINICAL STUDY EVALUATING ANAVEX3-71 FOR THE TREATMENT OF SCHIZOPHRENIA IN ADULTS ON STABLE ANTIPSYCHOTIC MEDICATION (ANAVEX3-71-SZ-001,NCT06245213). THE STUDY SUCCESSFULLY ACHIEVED ITS PRIMARY ENDPOINT, DEMONSTRATING THAT ANAVEX3-71 WAS SAFE AND WELL-TOLERATED.

ANAVEX LIFE SCIENCES ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 STUDY OF ANAVEX3-71 FOR THE TREATMENT OF SCHIZOPHRENIA

PUBLICATION TITLE: ORAL BLARCAMESINE PHASE IIB/III TRIAL CONFIRMS IDENTIFIED PRECISION MEDICINE PATIENT POPULATION  SIGNIFICANT BROAD CLINICAL AND QUALITY OF LIFE IMPROVEMENTS FOR EARLY ALZHEIMER'S DISEASE PATIENTS SIGNIFICANT IMPROVEMENT IN SELF-ASSESSED QUALITY OF LIFE (QOL-AD) SCORES INDICATING A REVERSAL OF NEGATIVE TRAJECTORY FOR ALZHEIMER'S DISEASE CLINICAL TRIAL PARTICIPANTS WAS OBSERVED USING A NOVEL PRECISION MEDICINE APPROACH, UP TO ~70% OF ALZHEIMER'S DISEASE PARTICIPANTS BENEFITED WITH UNPRECEDENTED EFFECT SIZE ORAL BLARCAMESINE TABLET, BY ENHANCING THE BRAIN'S AUTOPHAGY INTERNAL CLEARING MECHANISM COULD ALLEVIATE SIGNIFICANT MEDICAL AND ECONOMIC BURDEN PUBLICATION AVAILABLE ON MEDRXIV, IN SUBMISSION TO A PEER-REVIEWED MEDICAL JOURNAL NEW YORK, SEPT. 30, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY ANNOUNCED THE PUBLICATION ORAL BLARCAMESINE PHASE IIB/III TRIAL CONFIRMS IDENTIFIED PRECISION MEDICINE PATIENT POPULATION  SIGNIFICANT BROAD CLINICAL AND QUALITY OF LIFE IMPROVEMENTS FOR EARLY ALZHEIMER'S DISEASE PATIENTS TO BE AVAILABLE ONLINE AS A PREPRINT AT MEDRXIV, AND IN SUBMISSION TO A PEER-REVIEWED MEDICAL JOURNAL.

ANAVEX LIFE SCIENCES ANNOUNCES PUBLICATION OF ORAL BLARCAMESINE DESCRIBING A NEW CLASS OF CLINICAL PRECISION MEDICINE FROM PHASE IIB/III ALZHEIMER'S DISEASE TRIAL

NEW CLINICAL PRECISION MEDICINE POPULATION 48-WEEK DATA DEMONSTRATES UNPRECEDENTED COGNITIVE STABILIZATION IN EARLY ALZHEIMER'S DISEASE

ANAVEX LIFE SCIENCES ANNOUNCES ORAL BLARCAMESINE COGNITIVE RESILIENCE RESULTS APPROXIMATING NORMAL AGING IN NEW PRECISION MEDICINE CLINICAL DATA FROM PHASE IIB/III ALZHEIMER'S DISEASE TRIAL

NEW YORK, SEPT. 02, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, ANNOUNCED TODAY ANNOUNCED THAT CHRISTOPHER U.

ANAVEX LIFE SCIENCES TO PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE 2025

NEW YORK, AUG. 26, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY REPORTED A PEER-REVIEWED PUBLICATION IN THE JOURNAL ISCIENCE, ASCERTAINING THE PRECISE AUTOPHAGY MECHANISM OF SIGMAR-1 RECEPTOR (S1R/SIGMAR1) THROUGH BLARCAMESINE ACTIVATION, TITLED CONSERVED LIR-SPECIFIC INTERACTION OF SIGMA-1 RECEPTOR AND GABARAP.1

ANAVEX LIFE SCIENCES REPORTS NEW PUBLICATION IN MEDICAL JOURNAL HIGHLIGHTING THE ESTABLISHED PRECISE AUTOPHAGY MECHANISM WITH BLARCAMESINE

PRE-TREATMENT WITH BLARCAMESINE ENTIRELY PREVENTED ABETA-INDUCED COGNITIVE DECLINE CONFIRMED SIGNIFICANT BIOMARKER-RESPONSE IN HIPPOCAMPUS NEW YORK, AUG. 20, 2025 (GLOBE NEWSWIRE) -- ANAVEX LIFE SCIENCES CORP. (ANAVEX OR THE COMPANY) (NASDAQ: AVXL), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING INNOVATIVE TREATMENTS FOR ALZHEIMER'S DISEASE, PARKINSON'S DISEASE, SCHIZOPHRENIA, NEURODEVELOPMENTAL, NEURODEGENERATIVE, AND RARE DISEASES, INCLUDING RETT SYNDROME, AND OTHER CENTRAL NERVOUS SYSTEM (CNS) DISORDERS, TODAY REPORTED A PEER-REVIEWED PUBLICATION IN THE JOURNAL NEUROSCIENCE LETTERS, TITLED PREVENTION OF MEMORY IMPAIRMENT AND HIPPOCAMPAL INJURY WITH BLARCAMESINE IN AN ALZHEIMER'S DISEASE MODEL.1 THIS STUDY SHOWS THAT A PRE-TREATMENT WITH BLARCAMESINE PREVENTED AMYLOID BETA-INDUCED MEMORY IMPAIRMENT AND BRAIN OXIDATIVE INJURY SUGGESTING THAT BLARCAMESINE IS AN ATTRACTIVE CANDIDATE FOR ALZHEIMER'S DISEASE PHARMACOLOGICAL PREVENTION.

ANAVEX LIFE SCIENCES ANNOUNCES NEW PUBLICATION IN MEDICAL JOURNAL: BLARCAMESINE PREVENTED COGNITIVE IMPAIRMENT IN ANIMAL MODEL OF ALZHEIMER'S DISEASE

COMPANY TO HOST A WEBCAST TODAY AT 8:30 A.M. EASTERN TIME

ANAVEX LIFE SCIENCES REPORTSFISCAL 2025 THIRD QUARTER FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

WEBCAST AND CONFERENCE CALL TO BE HELD TUESDAY, AUGUST 12, 2025, 8:30 AM ET WEBCAST AND CONFERENCE CALL TO BE HELD TUESDAY, AUGUST 12, 2025, 8:30 AM ET

Anavex Life Sciences Corp.

AVXL

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Anavex Life Sciences Corp.

AVXL.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

AVXL